Today’s cyclodextrin:
If you follow CarboHyde, you saw that we recently added a new collaborative asset, KS-01, to our pipeline.
Here, you can find more info about this cyclodextrin that we developed together with the University of the Witwatersrand against triple-negative breast cancer and other types of cancer.
This collaboration marks a significant milestone in the fight against breast cancer, combining the strengths of two innovative organizations across continents. By pooling their resources, expertise, and networks, WITS and CarboHyde aim to bring this cutting-edge therapeutic to market, benefiting patients and healthcare systems worldwide.
Mandeep Kaur and her team already published a paper on this patented asset, so you can learn more about the science and check some available data here:
